About Combinati
Combinati is a company based in Palo Alto (United States) founded in 2015 by Megan Dueck, Andrew Zayac, and Paul Hung was acquired by Thermo Fisher Scientific in October 2021. Combinati has raised $5.83 million across 1 funding round from investors including Thermo Fisher Scientific. Combinati offers products and services including QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix. Combinati operates in a competitive market with competitors including NeuMoDx, GenMark Diagnostics, Stilla Technologies, Biomeme and InDex Pharmaceuticals, among others.
- Headquarter Palo Alto, United States
- Founders Megan Dueck, Andrew Zayac, Paul Hung
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Thermo Fisher Scientific Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.83 M (USD)
in 1 rounds
-
Latest Funding Round
$5.83 M (USD), Series A
May 02, 2018
- Investors
-
Employee Count
Not available
-
Acquired by
Thermo Fisher Scientific
(Oct 04, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Combinati
Combinati offers a comprehensive portfolio of products and services, including QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix.
System for precise digital PCR quantification in research applications.
Probe-based kits for detecting and quantifying nucleic acids accurately.
Master mix for various digital PCR applications in gene editing.
People of Combinati
Unlock access to complete
Unlock access to complete
Software Development Team
330 people
Leadership Team
169 people
Sales and Marketing
138 people
Human Resources and Administration
102 people
Product Management Team
68 people
Finance and Accounting
67 people
Senior Team
59 people
Operations Team
52 people
Unlock access to complete
Funding Insights of Combinati
Combinati has successfully raised a total of $5.83M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.83 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Combinati
Combinati has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Electron microscopy services and microanalysis instruments are provided.
|
Locked | Locked | Locked |
Investor details for Combinati
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Combinati
Investment portfolio details for Combinati
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Combinati
Detailed financials for Combinati
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Combinati Comparisons
Peer comparison for Combinati
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Combinati
Combinati operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NeuMoDx, GenMark Diagnostics, Stilla Technologies, Biomeme and InDex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Digital PCR solutions for research are developed and analyzed.
|
|
| Locked | Locked | Locked |
Smartphone-based DNA detection platform is developed for diagnostics.
|
|
| Locked | Locked | Locked |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| Locked | Locked | Locked |
Lab-on-a-chip technologies for miniaturized cell-biology testing are developed.
|
Detailed competitors of Combinati
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Combinati
Complete news archive for Combinati
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Combinati
Combinati was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Combinati is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Paul Hung is the current CEO of Combinati. They have also founded this company.
Combinati is a funded company, having raised a total of $5.83M across 1 funding round to date.
Combinati is developing an integrated digital PCR platform with injection-molded microfluidic consumables to advance biomedical research. It uses consumable technology that allows high-density reagent digitization on a standard format using a scalable manufacturing process. The industry-standard format allows the integration of pneumatics thermal optical and software modules into one benchtop instrument to offer a significant workflow advantage over current commercially available products. Its precision nucleic acid quantification platform would accelerate the adoption of dPCR technology in the clinic for disease prevention prognosis diagnosis as well as therapeutics efficacy monitoring.
Combinati's top competitors include GenMark Diagnostics, Stilla Technologies and NeuMoDx.
Combinati offers QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix.
Combinati has 1 investor. Key investors include Thermo Fisher Scientific.